In recent years, CTCF has been found to be mutated sporadically in diverse cancer types, such as leukemia, breast, uterine, and prostate cancers [19–23] and is involved in inhibiting cancer cell growth and clonogenicity [24]. The gene discussed is CTCF; the disease is prostate carcinoma.